CSL Limited (ASX:CSL – Get Free Report) insider Paul McKenzie purchased 8,275 shares of CSL stock in a transaction on Tuesday, September 3rd. The shares were acquired at an average cost of A$306.03 ($208.18) per share, with a total value of A$2,532,398.25 ($1,722,719.90).
CSL Stock Performance
The company has a debt-to-equity ratio of 62.80, a current ratio of 2.17 and a quick ratio of 1.68.
CSL Increases Dividend
The business also recently announced a Final dividend, which will be paid on Tuesday, October 1st. Stockholders of record on Tuesday, October 1st will be paid a $2.203 dividend. This is an increase from CSL’s previous Final dividend of $1.99. The ex-dividend date of this dividend is Sunday, September 8th. This represents a dividend yield of 0.73%. CSL’s dividend payout ratio is presently 49.69%.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Further Reading
- Five stocks we like better than CSL
- What is the Australian Securities Exchange (ASX)
- 3 Stocks to Watch as Firms Cut Costs Ahead of Potential Recession
- 3 Fintech Stocks With Good 2021 Prospects
- AST SpaceMobile: Reaching for the Stars or Overheating in Orbit?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Who Will Come Out on Top in the Chinese Coffee Wars?
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
